Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Total Non-Current Liabilities (2016 - 2025)

AC Immune has reported Total Non-Current Liabilities over the past 11 years, most recently at $18.4 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 9.67% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Dec 2025, down 9.67% year-over-year, with the annual reading at $18.4 million for FY2025, 9.67% down from the prior year.
  • Total Non-Current Liabilities was $18.4 million for Q4 2025 at AC Immune, up from $13.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $10.9 billion in Q2 2021 and troughed at $2.0 million in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $15.1 million (2024), against an average of $2.6 billion.
  • Year-over-year, Total Non-Current Liabilities crashed 99.98% in 2022 and then skyrocketed 170677.33% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $10.2 billion in 2021, then tumbled by 99.94% to $5.7 million in 2022, then skyrocketed by 170677.33% to $9.7 billion in 2023, then crashed by 99.79% to $20.3 million in 2024, then decreased by 9.67% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Total Non-Current Liabilities are $18.4 million (Q4 2025), $13.6 million (Q3 2025), and $19.9 million (Q2 2025).